Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities: 2018-2019

Historic Preferred Stock Liabilities for Black Diamond Therapeutics (BDTX) over the last 1 years, with Dec 2019 value amounting to $200.6 million.

  • Black Diamond Therapeutics' Preferred Stock Liabilities rose 230.05% to $200.6 million in Q4 2019 from the same period last year, while for Dec 2019 it was $200.6 million, marking a year-over-year increase of 230.05%. This contributed to the annual value of $200.6 million for FY2019, which is 230.05% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Preferred Stock Liabilities stood at $200.6 million for Q4 2019, which was up 73.15% from $115.8 million recorded in Q3 2019.
  • Black Diamond Therapeutics' 5-year Preferred Stock Liabilities high stood at $200.6 million for Q4 2019, and its period low was $60.8 million during Q4 2018.
  • For the 2-year period, Black Diamond Therapeutics' Preferred Stock Liabilities averaged around $99.7 million, with its median value being $60.8 million (2019).
  • Data for Black Diamond Therapeutics' Preferred Stock Liabilities shows a peak YoY surged of 230.05% (in 2019) over the last 5 years.
  • Over the past 2 years, Black Diamond Therapeutics' Preferred Stock Liabilities (Quarterly) stood at $60.8 million in 2018, then skyrocketed by 230.05% to $200.6 million in 2019.
  • Its Preferred Stock Liabilities stands at $200.6 million for Q4 2019, versus $115.8 million for Q3 2019 and $60.8 million for Q2 2019.